Use of Negative Pressure Wound Therapy Systems after Radical Vulvectomy for Advanced Vulvar Cancer.
Vittorio QuerciaGabriele SacconeAntonio RaffoneAntonio TravaglinoMariano FavalePietro D'AlessandroBruno ArduinoIlma Floriana CarboneLuigi InsabatoDiego RibuffoFulvio ZulloPublished in: Cancer investigation (2020)
A retrospective cohort study was performed to evaluate the efficacy of negative pressure wound therapy in improving vulvectomy healing. Women who underwent radical vulvectomy with complete inguinofemoral lymphadenectomy for advanced vulvar cancer were divided into two groups according to immediate postoperative care: patients treated with negative pressure wound therapy using the device applied on the site of the wound (including vulva and inguinal region), and patients receiving conventional care. 18 patients were included in the study. 7 (38.9%) women were treated with negative pressure wound therapy immediately after the surgery and were included in the intervention group, and 11 (61.1%) patients were included in the control group. Women who received negative pressure wound therapy had significantly lower length of stay in the hospital (14.2 ± 4.7 versus 17.1 ± 6.1 days, mean difference -6.90 days, 95% confidence interval -11.91 to -1.89), and significantly lower length for wound healing (-31.90 days, 95% confidence interval -43.48 to -20.32). In conclusion, the utilization of the negative wound pressure therapy may contribute to reduce hospitalization after radical vulvectomy for vulvar cancer. Large and well-designed randomized trials with cost effectiveness analyses are needed to confirm these findings.
Keyphrases
- wound healing
- surgical site infection
- healthcare
- end stage renal disease
- papillary thyroid
- ejection fraction
- pregnant women
- minimally invasive
- type diabetes
- squamous cell
- lymph node
- polycystic ovary syndrome
- emergency department
- patients undergoing
- sentinel lymph node
- chronic pain
- acute coronary syndrome
- atrial fibrillation
- skeletal muscle
- mesenchymal stem cells
- adipose tissue
- health insurance